Corvus Pharmaceuticals Inc (CRVS) Receives Consensus Recommendation of “Hold” from Brokerages

Share on StockTwits

Shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) have been assigned a consensus recommendation of “Hold” from the seven research firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $16.00.

CRVS has been the subject of a number of research reports. BidaskClub cut shares of Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, June 30th. Zacks Investment Research cut shares of Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 9th. ValuEngine cut shares of Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, June 18th. Wedbush restated an “outperform” rating on shares of Corvus Pharmaceuticals in a report on Wednesday, August 8th. Finally, Credit Suisse Group upgraded shares of Corvus Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their target price for the stock from $11.00 to $15.00 in a report on Wednesday, August 15th.

A number of large investors have recently modified their holdings of CRVS. Rhumbline Advisers acquired a new position in Corvus Pharmaceuticals in the 2nd quarter worth approximately $147,000. Acadian Asset Management LLC boosted its stake in Corvus Pharmaceuticals by 129.3% in the 2nd quarter. Acadian Asset Management LLC now owns 21,494 shares of the company’s stock worth $236,000 after purchasing an additional 12,119 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in Corvus Pharmaceuticals by 48.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 25,900 shares of the company’s stock worth $285,000 after purchasing an additional 8,400 shares during the period. Bank of New York Mellon Corp boosted its stake in Corvus Pharmaceuticals by 35.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 37,099 shares of the company’s stock worth $407,000 after purchasing an additional 9,782 shares during the period. Finally, International Biotechnology Trust PLC acquired a new position in Corvus Pharmaceuticals in the 2nd quarter worth approximately $892,000. Hedge funds and other institutional investors own 88.72% of the company’s stock.

Corvus Pharmaceuticals stock opened at $8.20 on Friday. The company has a market capitalization of $250.52 million, a PE ratio of -3.01 and a beta of -1.71. Corvus Pharmaceuticals has a 12-month low of $6.81 and a 12-month high of $16.31.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings data on Thursday, August 2nd. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.24. On average, analysts anticipate that Corvus Pharmaceuticals will post -1.98 EPS for the current fiscal year.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

See Also: What is the Book Value of a Share?

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply